Skip to content
Dr. Cannabis

Tetrahydrocannabivarin

THCV

A structural cousin of THC with dose-dependent and somewhat paradoxical behaviour: a CB1 antagonist at low doses, an agonist at high ones.

Preclinical onlyIntoxicating

Evidence status

Some early human metabolic research exists. Appetite and energy claims used in marketing are not clinically established.

THCV is often marketed as "diet weed" on the basis that CB1 antagonism suppresses appetite — the opposite of THC. There is early human work on metabolic parameters in type 2 diabetes, but appetite suppression as a consumer benefit is not established.

At higher doses THCV behaves more like THC and is intoxicating. Product labelling rarely makes clear which side of that curve a given dose lands on.

Commonly used for

  • • Marketed for appetite suppression and energy — not clinically established

Cautions

  • • Intoxicating at higher doses.
  • • Dose-response is biphasic, making effects hard to predict.

Sources

  1. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press, 2017.(DOI 10.17226/24625)Accessed 2026-08-15.